Companies in #KRAS-Driven Cancers
Found 1 company operating in this sector.
Nuvalent is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for oncology, with a particular focus on designing brain-penetrant, resistance-selective compounds. Its lead programs target ROS1 and ALK in non-small cell lung cancer, with additional programs in HER2 and KRAS. The company has positioned its chemistry platform to address the dual challenges of kinase resistance and CNS metastases, and in June 2026 signed a partnership with GSK giving GSK ex-US rights to two of its kinase inhibitors in a deal structured to take advantage of a post-ASCO share-price dip.